Target type: biologicalprocess
The removal of the apoptotic cell by phagocytosis, by a neighboring cell or by a phagocyte. [GOC:rk, PMID:15536015]
Engulfment of apoptotic cells is a critical process in multicellular organisms, ensuring the removal of dying cells without triggering inflammation and maintaining tissue homeostasis. This intricate process involves a series of molecular events orchestrated by a complex interplay of signaling pathways, receptors, and effector proteins. Here's a detailed description of the key steps:
**1. Recognition of Apoptotic Cells:**
* **Phosphatidylserine Exposure:** Apoptotic cells undergo significant changes in their cell membrane, with phosphatidylserine (PS) translocating from the inner leaflet to the outer leaflet. This "eat me" signal serves as a beacon for engulfing cells, allowing them to distinguish apoptotic cells from healthy ones.
* **Other "Eat Me" Signals:** Besides PS exposure, apoptotic cells also release other signals, such as calreticulin, thrombospondin, and the chemokine CX3CL1, which further contribute to their recognition.
**2. Binding to Receptors:**
* **Bridging Molecules:** Once apoptotic cells are recognized, engulfing cells utilize bridging molecules, like milk fat globule epidermal growth factor 8 (MFG-E8) and lactadherin, to bind to PS on the apoptotic cell surface. These molecules connect the engulfing cell's receptors to the "eat me" signals.
* **Engulfment Receptors:** Various receptors on the engulfing cell surface, including the tyrosine kinase receptors MerTK, Axl, and Tyro3, as well as the scavenger receptor CD36, bind to these bridging molecules, initiating the engulfment process.
**3. Internalization and Degradation:**
* **Phagocytosis:** Upon receptor activation, the engulfing cell extends pseudopodia, which surround the apoptotic cell and enclose it in a phagosome. This internalization process is driven by cytoskeletal rearrangements and the coordinated action of motor proteins.
* **Phagosome Maturation:** Once internalized, the phagosome undergoes maturation. It fuses with lysosomes, forming a phagolysosome, where the engulfed apoptotic cell is degraded by hydrolytic enzymes. The breakdown products are then recycled or released by the engulfing cell.
**4. Signaling Cascades:**
* **Downstream Signaling:** Receptor engagement triggers downstream signaling cascades, including the activation of PI3K, Akt, and Rac1 pathways, which play crucial roles in regulating cytoskeletal rearrangements and phagosome formation.
* **Anti-Inflammatory Effects:** Engulfment of apoptotic cells also triggers signaling pathways that suppress inflammation, ensuring that the removal of dead cells does not trigger an immune response.
**5. Regulation and Homeostasis:**
* **Fine-Tuned Control:** Engulfment of apoptotic cells is a tightly regulated process, ensuring that only apoptotic cells are removed, while healthy cells remain untouched. The intricate balance of signals and receptors involved in this process ensures proper tissue homeostasis.
* **Immune System Regulation:** The clearance of apoptotic cells by phagocytes is essential for maintaining immune tolerance and preventing autoimmunity. By efficiently removing apoptotic cells, the immune system avoids recognizing them as foreign invaders.
**In Conclusion:**
Engulfment of apoptotic cells is a fundamental biological process that plays a critical role in tissue homeostasis, immune regulation, and the maintenance of cellular integrity. This complex process involves the recognition of apoptotic cells, binding to receptors, internalization, and degradation, all orchestrated by intricate signaling pathways and cellular machinery.'
"
Protein | Definition | Taxonomy |
---|---|---|
Ras-related C3 botulinum toxin substrate 1 | A Ras-related C3 botulinum toxin substrate 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P63000] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
fasudil | fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia. fasudil: intracellular calcium antagonist; structure in first source | isoquinolines; N-sulfonyldiazepane | antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent |
ketorolac | 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively. ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure. Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed) | amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate | analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug |
sanguinarine chloride | |||
chelerythrine chloride | |||
perifosine | ammonium betaine; phospholipid | EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | |
ruboxistaurin | ruboxistaurin: inhibits protein kinase C beta; structure in first source | ||
s 1033 | (trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide | anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor | |
sotrastaurin | sotrastaurin : A member of the class of maleimides that is maleimide which is substituted at position 3 by an indol-3-yl group and at position 4 by a quinazolin-4-yl group, which in turn is substituted at position 2 by a 4-methylpiperazin-1-yl group. It is a potent and selective inhibitor of protein kinase C and has been investigated as an immunosuppresant in renal transplant patients. sotrastaurin: a potent protein kinase C-selective inhibitor; structure in first source | indoles; maleimides; N-alkylpiperazine; N-arylpiperazine; quinazolines | anticoronaviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunosuppressive agent |
gdc-0973 | cobimetinib : A member of the class of N-acylazetidines obtained by selective formal condensation of the carboxy group of 3,4-difluoro-2-(2-fluoro-4-iodoanilino)benzoic acid with the secondary amino group from the azetidine ring of 3-[(2S)-piperidin-2-yl]azetidin-3-ol. An inhibitor of mitogen-activated protein kinase that is used (as its fumarate salt) in combination with vemurafenib for the treatment of patients with unresectable or metastatic melanoma. cobimetinib: has antineoplastic activity; structure in first source | aromatic amine; difluorobenzene; N-acylazetidine; organoiodine compound; piperidines; secondary amino compound; tertiary alcohol | antineoplastic agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor |
azd5438 | sulfonamide | ||
nsc 23766 | NSC 23766 trihydrochloride : A hydrochloride resulting from the formal reaction of NSC 23766 with 3 mol eq. of hydrogen chloride. An inhibitor of the signalling G-protein known as RAC1 (Ras-related C3 botulinum toxin substrate 1). Rac1 inhibitor : Any inhibitor of Rac1. | hydrochloride | antiviral agent; apoptosis inducer; EC 3.6.5.2 (small monomeric GTPase) inhibitor; muscarinic antagonist |
at13148 | |||
poziotinib | HM781-36B: antitumor irreversible Pan-HER inhibitor for treatment of gastric cancer | acrylamides; aromatic ether; dichlorobenzene; diether; monofluorobenzenes; N-acylpiperidine; quinazolines; secondary amino compound; substituted aniline | antineoplastic agent; apoptosis inducer; epidermal growth factor receptor antagonist |
bay 869766 | |||
gilteritinib | gilteritinib : A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation. gilteritinib: an FLT3/AXL protein tyrosine kinase inhibitor | aromatic amine; monomethoxybenzene; N-methylpiperazine; oxanes; piperidines; primary carboxamide; pyrazines; secondary amino compound | antineoplastic agent; apoptosis inducer; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor |
glpg0634 |